The Food and Drug Administration (FDA) last week approved Bristol Myers Squibb’s antipsychotic drug Cobenfy (xanomeline and trospium chloride), the first schizophrenia treatment with an entirely ...

The Food and Drug Administration approved Cobenfy, a twice-a-day medication that is a new kind of treatment for schizophrenia in adults. Steve Belkowitz/Bristol Myers Squibb hide caption ...

N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

The US Food and Drug Administration has approved Cobenfy, also known as KarXT, a new schizophrenia treatment. The drug was developed by Karuna Therapeutics, which was bought by Bristol Myers ...

Cobenfy, a new drug made by Bristol Myers Squibb and approved by the FDA last week, triggers muscarinic receptors instead of dopamine receptors. It's the first schizophrenia treatment to do so.

Cobenfy “is getting a lot of ballyhoo, as any new drug does,” Greiling said. “It’s just a nonstarter for me unless it turns out that it’s better than clozapine.” ...

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.

More importantly, the drug could deliver huge value to the healthcare system. In 2019, the economic burden of schizophrenia in America was $343 billion.If Cobenfy can reduce even a fraction of ...

FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million ...

He added that available data suggest AbbVie’s schizophrenia drug likely offers lower efficacy but better safety than Cobenfy, but the BMS drug will have about an 18-month head start.

Cobenfy is the first new drug to get Food and Drug Administration approval to treat schizophrenia with more manageable side effects than the leading treatment. (Photo courtesy of Bristol Myers Squibb) ...

This image provided by Bristol Myers Squibb in October 2024 shows the company's drug Cobenfy, which the U.S. Food and Drug Administration approved for the treatment of schizophrenia in September 2024.